ArsenalBio has picked up $85m in funding to commercialise immunotherapy engineering research resulting from a collaboration that includes PICI and UCSF.

ArsenalBio, a US-based immunotherapy developer leveraging research originating from Parker Institute for Cancer Immunotherapy (PICI),  attracted $85m of series A funding yesterday from investors including the institute and University of California, San Francisco (UCSF)’s Investment Company.
Spinout-focused investment firm Osage University Partners also took part in the round, as did family office Euclidean Capital and venture capital firms Westlake Village BioPartners and Kleiner Perkins.
Founded earlier in 2019, ArsenalBio plans to develop T-cell therapies using computational design methods…